Anti-PD-1/PD-L1 Antibodies Combine with Chemotherapy or CTLA4 Antibodies for First-Line Treatment of Advanced Lung Cancer

被引：0
|
作者：
Fan, Y. [1 ]
Xu, X. [2 ]
机构：
[1] Zhejiang Canc Hosp, Chemotherapy, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Prov Canc Hosp, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
lung cancer; Checkpoint inhibitors; chemotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.07-057
引用
收藏
页码：S2149 / S2150
页数：2
相关论文
共 50 条
  • [31] Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
    Philips, George K.
    Atkins, Michael
    INTERNATIONAL IMMUNOLOGY, 2015, 27 (01) : 39 - 46
  • [32] Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment
    Passat, Tilda
    Touchefeu, Yann
    Gervois, Nadine
    Jarry, Anne
    Bossard, Celine
    Bennouna, Jaafar
    BULLETIN DU CANCER, 2018, 105 (11) : 1033 - 1041
  • [33] Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Festino, Lucia
    Botti, Gerardo
    Lorigan, Paul
    Masucci, Giuseppe V.
    Hipp, Jason D.
    Horak, Christine E.
    Melero, Ignacio
    Ascierto, Paolo A.
    DRUGS, 2016, 76 (09) : 925 - 945
  • [34] Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Lucia Festino
    Gerardo Botti
    Paul Lorigan
    Giuseppe V. Masucci
    Jason D. Hipp
    Christine E. Horak
    Ignacio Melero
    Paolo A. Ascierto
    Drugs, 2016, 76 : 925 - 945
  • [35] Prospect of combination of anti-PD-1/PD-L1 therapy and other therapeutics for treatment of lung cancer
    WANG Lu-yao
    YAO Rui-xue
    XU Qian-qian
    LIU Jia
    中国药理学与毒理学杂志, 2019, (10) : 888 - 888
  • [36] Activity of Anti-PD-1 in Murine Tumor Models: Role of "Host" PD-L1 and Synergistic Effect of Anti-PD-1 and Anti-CTLA-4
    Korman, Alan
    Chen, Bing
    Wang, Changyu
    Wu, Linda
    Cardarelli, Pina
    Selby, Mark
    JOURNAL OF IMMUNOLOGY, 2007, 178
  • [37] Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer
    Wang, Luyao
    Ma, Qingxia
    Yao, Ruixue
    Liu, Jia
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 79
  • [38] Glyco-signatures in patients with advanced lung cancer during anti-PD-1/PD-L1 immunotherapy
    Cao, Xinyi
    Hu, Zhihuang
    Sheng, Xiangying
    Sun, Zhenyu
    Yang, Lijun
    Shu, Hong
    Liu, Xiaojing
    Yan, Guoquan
    Zhang, Lei
    Liu, Chao
    Zhang, Ying
    Wang, Huijie
    Lu, Haojie
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2024, 56 (08) : 1099 - 1107
  • [39] Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer
    Lurain, Kathryn
    Ramaswami, Ramya
    Yarchoan, Robert
    Uldrick, Thomas S.
    CURRENT HIV/AIDS REPORTS, 2020, 17 (05) : 547 - 556
  • [40] Clinical benefit of anti-PD-1/PD-L1 plus chemotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic non-small cell lung cancer (NSCLC)
    Landre, Thierry
    Chouaid, Christos
    Sadaoui, Nassyma
    Bouharati, Djamila
    Taleb, Cherifa
    JOURNAL OF CHEMOTHERAPY, 2024, 36 (08) : 675 - 681
12345